IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review
AbstractInterleukin-33 (IL-33) is a cytokine belonging to the IL-1 family, playing a role in inflammatory, infectious and autoimmune diseases and expressed in the cellular nucleus in several tissues. High levels of IL-33 are expressed in epithelial barrier tissues and endothelial barriers. ST2 is a receptor for IL-33, expressed selectively on a subset of Th2 cells, mediating some of their functions. The IL-33/ST2 axis plays an important role in several acute and chronic inflammatory diseases, including asthma and rheumatoid arthritis. Different disorders are related to the activity of IL-33, ST2, or their axis, including cardiovascular disease or renal disturbances. Therefore, in the present work, a literature review was conducted, covering the period from 1 January 2000 to 30 November 2018, in PubMed, ScienceDirect, and Google Scholar database, to assess the involvement of the IL-33/ST2 axis in diabetic kidney disease. 6 articles directly dealing with the argument were identified, highlighting a clear link between IL-33/ST2 axis and diabetic kidney disease or related nephropathy. Overall, the involvement of ST2 seems to be more predictive than IL-33, especially in investigating the deterioration of kidney function; however, both compounds are pivotal in the field of renal diseases. Future studies are required to confirm the scientific evidences on larger and more heterogeneous cohorts. View Full-Text
Share & Cite This Article
Tonacci, A.; Quattrocchi, P.; Gangemi, S. IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review. Medicina 2019, 55, 50.
Tonacci A, Quattrocchi P, Gangemi S. IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review. Medicina. 2019; 55(2):50.Chicago/Turabian Style
Tonacci, Alessandro; Quattrocchi, Paolina; Gangemi, Sebastiano. 2019. "IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review." Medicina 55, no. 2: 50.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.